For patients treated with BRAF inhibitors, while the poor response to targeted therapy can be explained by constitutive activation of alternative signaling pathways (Prahallad et al., 2012), the lack of correlation between BRAFV600E adjMAFs measured in CRC primary tissues and TTP in the metastatic setting may be related to a potential shift in clonality status of BRAFV600E events from primaries to metastases. Here, BRAF is linked to colorectal carcinoma.